Drug–drug interaction between letermovir and ciclosporin in allogeneic haematopoietic cell transplantation recipients
Letermovir significantly decreased CsA metabolism in HSCT patients through CYP3A4 inhibition, with clinical implications for dosing precision. Close therapeutic drug monitoring (generally twice weekly) is therefore recommended during letermovir initiation and discontinuation to mitigate risks of subtherapeutic levels or toxicity. This study highlights the significance of assessing DDIs in HSCT, where inflammation modulates metabolic interactions resulting in a complex interplay such as a disease-drug-drug interaction (D-DDI).
Authors
- Mathilde Bories (ORCID: https://orcid.org/0000-0001-9092-4298)
- Pascal Le Corre (ORCID: https://orcid.org/0000-0003-4483-0957)
- David Malnoë (ORCID: https://orcid.org/0000-0002-5650-852X)
- Tony Marchand (ORCID: https://orcid.org/0000-0003-4932-2169)
Institutions
- Inserm (FR)
- École des Hautes Études en Santé Publique (FR)
- Institut de Recherche en Santé, Environnement et Travail (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
- Microenvironment and B-cells: Immunopathology, Cell, Differentiation and Cancer (FR)
- Université de Rennes (FR)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1093/jac/dkaf063
- Citations
- 3
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 4.06